Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct 17;4(1):pkz078.
doi: 10.1093/jncics/pkz078. eCollection 2020 Feb.

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)

Justin C Brown  1 , Sui Zhang  1 , Fang-Shu Ou  1 , Alan P Venook  1 , Donna Niedzwiecki  1 , Heinz-Josef Lenz  1 , Federico Innocenti  1 , Bert H O'Neil  1 , James E Shaw  1 , Blase N Polite  1 , Crystal S Denlinger  1 , James N Atkins  1 , Richard M Goldberg  1 , Kimmie Ng  1 , Robert J Mayer  1 , Charles D Blanke  1 , Eileen M O'Reilly  1 , Charles S Fuchs  1 , Jeffrey A Meyerhardt  1
Affiliations

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)

Justin C Brown et al. JNCI Cancer Spectr. .

Abstract

Background: Diabetes is a prognostic factor for some malignancies, but its association with outcome in patients with advanced or metastatic colorectal cancer (CRC) is less clear.

Methods: This cohort study was nested within a randomized trial of first-line chemotherapy and bevacizumab and/or cetuximab for advanced or metastatic CRC. Patients were enrolled at 508 community and academic centers throughout the National Clinical Trials Network. The primary exposure was physician-documented diabetes at the time of enrollment. The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS) and adverse events. Tests of statistical significance were two-sided.

Results: Among 2326 patients, 378 (16.3%) had diabetes. The median follow-up time was 6.0 years. We observed 1973 OS events and 2173 PFS events. The median time to an OS event was 22.7 months among those with diabetes and 27.1 months among those without diabetes (HR = 1.27, 95% CI = 1.13 to 1.44; P < .001). The median time to a PFS event was 9.7 months among those with diabetes and 10.8 months among those without diabetes (HR = 1.16, 95% CI = 1.03 to 1.30; P = .02). Patients with diabetes were more likely to experience no less than grade 3 hypertension (8.1% vs 4.4%; P = .054) but were not more likely to experience other adverse events, including neuropathy.

Conclusions: Diabetes is associated with an increased risk of mortality and tumor progression in patients with advanced or metastatic CRC. Patients with diabetes tolerate first-line treatment with chemotherapy and monoclonal antibodies similarly to patients without diabetes.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials.
Figure 2.
Figure 2.
Subgroup analyses of progression-free survival and overall survival estimates by diabetes status. BMI, kg/m2. BMI = body mass index; ECOG = Eastern Cooperative Oncology Group; FOLFIRI = 5-fluorouracil, leucovorin, irinotecan; mFOLFOX6 = 5-fluorouracil, leucovorin, oxaliplatin.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A.. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. - PubMed
    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2017.
    1. Larsson SC, Orsini N, Wolk A.. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–1687. - PubMed
    1. Gross CP, Guo Z, McAvay GJ, et al. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc. 2006;54(12):1898–1904. - PubMed
    1. Dehal AN, Newton CC, Jacobs EJ, et al. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012;30(1):53–59. - PubMed

LinkOut - more resources